Artiva Biotherapeutics, Inc. Operating Expenses
Artiva Biotherapeutics, Inc. (ARTV) reported Operating Expenses of $26.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $26.89M, a 17.89% increase year-over-year.
- Artiva Biotherapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $24.43M, a 10.19% increase year-over-year.
- Artiva Biotherapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $21.93M, a 20.06% increase year-over-year.
- Artiva Biotherapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $22.90M, a 24.88% increase year-over-year.
- Artiva Biotherapeutics, Inc. operating expenses for fiscal 2025 was $89.81M, a 32.99% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. operating expenses for fiscal 2024 was $67.53M, a 5.25% increase from fiscal 2023.
- Artiva Biotherapeutics, Inc. operating expenses for fiscal 2023 was $64.16M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.89M 10-Q · filed 2026-08-06 | $51.32M 10-Q · filed 2026-08-06 | $73.25M derived: sum of 3 quarters · filed 2026-08-06 | $96.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.43M 10-Q · filed 2026-05-08 | $46.36M derived: sum of 2 quarters · filed 2026-05-08 | $69.26M derived: sum of 3 quarters · filed 2026-05-08 | $92.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $44.83M derived: sum of 2 quarters · filed 2026-03-10 | $67.64M derived: sum of 3 quarters · filed 2026-08-06 | $89.81M 10-K · filed 2026-03-10 |
| 2025-09-30 | $22.90M 10-Q · filed 2025-11-12 | $45.71M derived: sum of 2 quarters · filed 2026-08-06 | $67.88M 10-Q · filed 2025-11-12 | $86.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $22.81M 10-Q · filed 2026-08-06 | $44.98M 10-Q · filed 2026-08-06 | $63.25M derived: sum of 3 quarters · filed 2026-08-06 | $81.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.17M 10-Q · filed 2026-05-08 | $40.44M derived: sum of 2 quarters · filed 2026-05-08 | $58.77M derived: sum of 3 quarters · filed 2026-05-08 | $74.96M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $36.60M derived: sum of 2 quarters · filed 2026-03-10 | $52.79M derived: sum of 3 quarters · filed 2026-03-10 | $67.53M 10-K · filed 2026-03-10 |
| 2024-09-30 | $18.34M 10-Q · filed 2025-11-12 | $34.52M derived: sum of 2 quarters · filed 2025-11-12 | $49.27M 10-Q · filed 2025-11-12 | $63.59M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $16.19M 10-Q · filed 2025-08-06 | $30.93M 10-Q · filed 2025-08-06 | $45.25M derived: sum of 3 quarters · filed 2025-08-06 | $61.10M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $14.74M 10-Q · filed 2025-05-08 | $29.06M derived: sum of 2 quarters · filed 2025-05-08 | $44.91M derived: sum of 3 quarters · filed 2025-05-08 | $60.23M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $30.16M derived: sum of 2 quarters · filed 2025-03-24 | $45.49M derived: sum of 3 quarters · filed 2025-03-24 | $64.16M 10-K · filed 2025-03-24 |
| 2023-09-30 | $15.85M 10-Q · filed 2024-11-12 | $31.17M derived: sum of 2 quarters · filed 2024-11-12 | $49.84M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $15.32M 10-Q · filed 2024-08-29 | $34.00M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |